Home/ Supplements/ Omega 3/ PNV OB+DHA Softgel

PNV OB+DHA Softgel

product on market Softgel Capsule PharmaPure Rx Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · grounded in 1 source · methodology

Docosahexaenoic acid (DHA) is an omega-3 fatty acid supported by strong evidence for supporting cognitive function and cardiovascular health. Research indicates it plays a critical role in maintaining the structural integrity of brain cell membranes. The ingredient profile demonstrates a high safety rating for general consumption.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for PNV OB+DHA Softgel
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Softgel(s)
Serving Size
Fat/Fatty Acid
Product Type
100%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Market median: 750.0mg (447 products) 393 studies (A:18, B:204)

Other Ingredients

Gelatin Water Glycerin Polysorbate 80
Claims

Label Claims — Verification

Unverified All Other
Info

Product Information

Directions for Use

DOSAGE AND ADMINISTRATION: Before, during and after pregnancy, one caplet and one softgel taken by mouth daily, or as directed by a physician. The caplet and softgel may be taken together or at different times of the day.

Warnings & Precautions

Caution should be exercised to ensure that the prescribed dose of DHA does not exceed 1 gram (1,000 mg) per day.

Contains Soy.

Formulation Notes

250 mg DHA Softgel

Contains Stool Softener

INDICATIONS: PNNV OB+DHA is a prescription regimen of prenatal multivitamin, multi-mineral and Omega-3 fatty acid supplements indicated for use in improving the nutritional status of women throughout pregnancy and in the post-natal period for both lactating and non-lactating mothers.

30 Softgels: Docosahexaenoic Acid (DHA) 250 mg

Each PNV OB+DHA softgel contains: 250 mg Docosahexaenoic Acid (DHA)

May contain Vanillin.

Also contains Eicosapentaenoic Acid (EPA) and other Omega-3 Fatty Acids.

Contains Soy.

Additional Information

30-Day Supply

PNV OB+DHA is also useful in improving the nutritional status prior to conception.

Consult package insert for full prescribing information.

Rx Only

DHA is contained in the oil derived from fish (tuna).

Cloudiness of the softgel is a characteristic of natural fish oil.

PharmaPureRx

List No. 11560 ENY Rev. 00-33265

Metadata

Product Details

UPC / SKU7 31477 47177 1
DSLD Entry Date2014-10-10
Product TypeFat/Fatty Acid
FormSoftgel Capsule
DSLD ID37180
Data Updated2026-04-11
Research

Research Evidence

495
Research Sources
56
Avg Quality
222
Meta Analysis
104
Clinical Trial
72
Rct
69
Systematic Review
11
Guideline
5
Cochrane Review
5
Regulatory Source
3
Narrative Review
1
Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
View all evidence for Omega 3 →
Compare

Similar Products

View all Omega 3 products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.